Home About S.M.B. Research & Development Galenic Products Licensing Jobs Pharmacovigilance Contact
Company Profile Vision and Mission History International Presence  
 
HISTORY
S.M.B. was established in Brussels in 1953 with the task of delivering family medicine on the local market.

In the pharmaceutical sector, innovation is a determinant factor. In 1978, with the arrival of a new management team, the activities of S.M.B. had been focused on the innovative developments of oral drug delivery systems with the aim of bringing on the market products different from competitors and positioning the company on a high added value sector (1980-1990).

This policy came out with a significant effort in favour of the R&D sector in order to push the creation of innovative drug formulations.

With the arrival of new products, it became obvious and necessary for S.M.B. to find new markets. Obvious, because the company has always wanted to offer the best drugs to the greatest number; and necessary to cover the costs of the R&D and production. Indeed, the Belgian pharmaceutical market, although dynamic, remains relatively modest.

A new high-tech manufacturing unit (S.M.B. Technology) was built in 1988 in order to face the new challenges of the company amongst other on the international markets.

In the past, the production was located in Brussels. Nevertheless, for environmental and space reasons, it has been moved in Wallonia. The factory complies now all necessary certifications of quality such as ISO 9002 and GMP (Good Manufacturing Practice) and offers a flexible high potential of production to satisfy our worlwide partners.

This manufacturing unit concentrates a significant part of the investments of the company in modern production and laboratory equipments to guarantee excellent volumes and quality.

TIME LINE
 
1953 - Foundation of S.M.B. in Brussels, Belgium
1978 - New Managing Director, Mr. Ph. Baudier
Collaboration with Professor Jaminet (university of Liege)
1988 - Creation of S.M.B. Technology in Marche-en-Famenne, Belgium
1994 - Continued GMP compliance at both European and world level for the scaling-up of new and existing products
1998 - ISO 9002 certification on June 25 for S.M.B. Technology
Creation of Galephar Pharma GmbH Germany)
Marketing alliance with Glaxo Wellcome in Belgium & Luxembourg
1999 - Creation of Galephar M/F First EU Divule® registration
2000 - Orphan Drug Status granted for our novel mucolytic agent Nacystelyn, reference in the US (FDA) and in Europe (EMEA)
2002 - First registration of once daily Tramadol in an European Reference Member State
Creation of Galephar Portugal
2003 - Registration of once daily Tramadol in 10 European countries by MRP
Creation of Galephar Poland
2004 - Successful registration of Fenofibrate Lidose® in Canada
Creation of Galephar Turkey

Export exceed 50% of turnover

Successful registration of Formoterol 12 µg DPI in Netherlands, Italy, Portugal, Germany, Poland,...

 Belgian launches of D-Cure Plus and Amlodipine 10 mg
2006 - Belgian registration of Isotretinoin Supra 8 – 16 mg

International License Agreement signed with Grünenthal GmbH for Tramadol once daily
2007 - First registration in South Korea : fenofibrate Lidose 160 mg
  - First registration in Australia : omeprazole tablets
  2008 - Successful European registration of clarithromycine 200 mg once daily capsule
  - First registration of buprenorphine sublingual tablet in Greece
  - Exports reach 70 % of turnover